C4 Therapeutics, Inc. Restructuring Charges
C4 Therapeutics, Inc. (CCCC) reported Restructuring Charges of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-26
- C4 Therapeutics, Inc. restructuring charges for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- C4 Therapeutics, Inc. restructuring charges for fiscal 2024 was $2.44M.
- C4 Therapeutics, Inc. restructuring charges for fiscal 2023 was $0.00.
| Period end | Restructuring Charges | Restructuring Charges 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |
| 2024-12-31 | $2.44M 10-K · filed 2026-02-26 | |
| 2024-01-09 | $2.40M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |